Association of Markers of Bone Mineral Disease and Left Ventricular Hypertrophy in Patients of Chronic Kidney Disease

1 Coresh J. Update on the Burden of CKD. Journal of the American Society of Nephrology 2017; 28:1020–2. https://doi.org/10.1681/ASN.2016121374 Search in Google Scholar

2 Agarwal SK. Chronic kidney disease and its prevention in India. Kidney International Supplement 2005;68: S41-5. https://doi.org/10.1111/j.1523-1755.2005.09808.Wang H, Naghavi M, Allen C, et al. Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study. Lancet 2015; 388:1459–544. Benz K, Hilgers KF, Daniel C, Amann K. Vascular Calcification in Chronic Kidney Disease: The Role of Inflammation. Int J Nephrol. 2018:4310379. https://doi:10.1155/2018/4310379. Search in Google Scholar

3 Bulbul MC, Dagel T, Afsar B, et al. Disorders of lipid metabolism in chronic kidney disease. Blood Purification 2018; 46:144-52, https://doi.org/10.1159/000488816 Search in Google Scholar

4 Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. Journal of the American Society of Nephrology 1998;9:S16-23. https//doi:10.1053/ajkd.1998.v32.pm9820470 Search in Google Scholar

5 Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. Journal of the American Society of Nephrology 2001; 12:1079-84. https/doi:10.1681/ASN.V1251079 Search in Google Scholar

6 Levin A, Singer J, Thompson CR, et al. Prevalent left ventricular hypertrophy in the pre-dialysis population: identifying opportunities for intervention. American Journal of Kidney Diseases 1996; 27:347-54. https//doi:10.1016/s0272-6386(96)90357-1 Search in Google Scholar

7 Ritz E, Wanner C. The challenge of sudden death in dialysis patients. Clinical Journal of the American Society of Nephrology. 2008; 3:920–9. https//doi:10.2215/CJN.04571007 Search in Google Scholar

8 Gross ML, Ritz E. Hypertrophy and fibrosis in the cardiomyopathy of uremia – beyond coronary heart disease. Seminars in Dialysis 2008; 21:308–18. https//doi:10.1111/j.1525139X.2008.00454.x Search in Google Scholar

9 Ritz E. Left ventricular hypertrophy in renal disease: beyond preload and afterload. Kidney International 2009; 75:771–3. https//doi:10.1038/ki.2009.35 Search in Google Scholar

10 Yilmaz BA, Mete T, Dincer I, et al. Predictors of left ventricular hypertrophy in patients with chronic kidney disease. Renal Failure 2007;29: 303-7. httpss//DOI:10.1080/08860220601166529 Search in Google Scholar

11 Cottone S, Nardi E, Mulè G, et al. Association between biomarkers of inflammation and left ventricular hypertrophy in moderate chronic kidney disease. Clinical Nephrology 2007; 67:209-16. https//doi:10.5414/cnp67209 Search in Google Scholar

12 Achinger SG, Ayus JC. Left ventricular hypertrophy: is hyperphosphatemia among dialysis patients a risk factor? Journal of the American Society of Nephrology. 2006; 17:S255-61. https//doi:10.1681/ASN.2006080923 Search in Google Scholar

13 Hsu HJ, Wu MS. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci. 2009; 337:116-22. https//doi:10.1097/MAJ.0b013e3181815498 Search in Google Scholar

14 Gutiérrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119:2545-52. https//doi:10.1161/CIRCULATIONAHA.108.844506 Search in Google Scholar

15 Devereux RB, Lutas EM, Casale PN, et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol. 1984; 4:1222-30. https//doi:10.1016/s0735-1097(84)80141-2 Search in Google Scholar

16 Krane V, Winkler K, Drechsler C, et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney International 2008; 74:1461–7. https//doi:10.1038/ki.2008.484 Search in Google Scholar

17 Paoletti E, Bellino D, Cassottana P, et al. Left ventricular hypertrophy in nondiabetic pre-dialysis CKD. American Journal of Kidney Diseases 2005; 46:320-7. https//doi:10.1053/j.ajkd.2005.04.031 Search in Google Scholar

18 Kimura T, Iio K, Obi Y, Hayashi T. Left ventricular hypertrophy in pre-dialysis chronic kidney disease: impact of cardiomuscular stress markers. Nippon Jinzo Gakkai Shi 2007; 49:1007-13.b. https://doi.org/10.14842/jpnjnephrol1959.49.1007 Search in Google Scholar

19 Brancaccio D, Cozzolino M. The mechanism of calcium deposition in soft tissues. Contributions to Nephrology 2005; 149: 279–86. https//doi:10.1159/000085689 Search in Google Scholar

20 Fang Y, Ginsberg C, Sugatani T, et al. Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney International 2014; 85:142-50. doi: 10.1038/ki.2013.271 Search in Google Scholar

21 Pereira RC, Juppner H, Azucena-Serrano CE, et al. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone. 2009; 45:1161-8. https//doi:10.1016/j.bone.2009.08.008 Search in Google Scholar

22 Zhou C, Wang F, Wang JW, et al. Mineral and Bone Disorder and Its Association with Cardiovascular Parameters in Chinese Patients with Chronic Kidney Disease. Chinese Medical Journal 2016; 129:2275-80. https//doi:10.4103/0366-6999.190678 Search in Google Scholar

23 Chue CD, Edwards NC, Moody WE, et al. Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study. Heart 2012; 98:219-24. https//doi:10.1136/heartjnl-2011-300570 Search in Google Scholar

24 Wahl P, Wolf M. FGF23 in chronic kidney disease. Advances in Experimental Medicine and Biology 2012; 728:107-25. https//doi:10.1007/978-1-4614-0887-1_8 Search in Google Scholar

25 Isakova T, Xie H, Yang W, et al. Chronic Renal Insunjciency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305:2432-9. https//doi:10.1001/jama.2011.826 Search in Google Scholar

26 Liu X, Xie R, Liu S. Rat parathyroid hormone 1–34 signals through the MEK/ERK pathway to induce cardiac hypertrophy. Int J Med Res. 2008;36:942–50. Search in Google Scholar

27 Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121:4393-408. https//doi:10.1172/JCI46122. Epub 2011 Oct 10. Search in Google Scholar

28 Nielsen TL, Plesner LL, Warming PE, et al. FGF23 in hemodialysis patients is associated with left ventricular hypertrophy and reduced ejection fraction. Nefrologia (Engl Ed) 2019; 39:258-68. https//doi:10.1016/j.nefro.2018.10.007">https//doi:10.1016/j.nefro.2018.10.007 Search in Google Scholar